XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jan. 31, 2018
Jan. 31, 2017
Operating activities    
Net (loss) income $ (106) $ 23,552
Adjustments to reconcile net (loss) income to net cash used in operating activities:    
Depreciation and amortization 11,408 10,601
Deferred income taxes 3,212 (12,868)
Provision for doubtful accounts receivable 696 126
Realized loss (gain) on marketable securities 9 (305)
Interest in the equity of investments (77) (295)
Stock-based compensation 1,797 2,128
Change in assets and liabilities:    
Restricted cash and cash equivalents (3,663) 4,098
Trade accounts receivable (4,568) (8,189)
Prepaid expenses, other current assets and other assets (15,109) (1,432)
Trade accounts payable, accrued expenses, other current liabilities and other liabilities (20,344) (15,010)
Customer deposits 4,481 (1,177)
Deferred revenue (4,710) (2,043)
Net cash used in operating activities (26,974) (814)
Investing activities    
Capital expenditures (10,931) (10,543)
Proceeds from sale of interest in Straight Path IP Group Holding, Inc. 6,000
Purchase of IP Interest from Straight Path Communications Inc. (6,000)
Payment for acquisition, net of cash acquired (1,827)
Cash used for investments (8,304)
Purchases of marketable securities (19,797) (17,209)
Proceeds from maturities and sales of marketable securities 31,610 16,848
Net cash provided by (used in) investing activities 882 (21,035)
Financing activities    
Dividends paid (9,440) (8,765)
Distributions to noncontrolling interests (717) (817)
Proceeds from borrowings under revolving credit facility 19,080
Repayments of borrowings under revolving credit facility (19,080)
Proceeds from exercise of stock options 835
Proceeds from sale of member interests in CS Pharma Holdings, LLC. 1,250
Repurchases of Class B common stock (61) (1,838)
Net cash used in financing activities (10,218) (9,335)
Effect of exchange rate changes on cash and cash equivalents 592 (829)
Net decrease in cash and cash equivalents (35,718) (32,013)
Cash and cash equivalents at beginning of period, including $5,716 held for sale at July 31, 2017 96,060 109,537
Cash and cash equivalents at end of period, including $6,287 held for sale at January 31, 2018 60,342 77,524
Supplemental schedule of non-cash investing and financing activities    
Reclassification of liability for member interests in CS Pharma Holdings, LLC $ 8,750